Stock Evaluator: Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience, Inc. NAGE

$3.40 0.08 2.41%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 648,508
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Consumer Staples Personal Care Products

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Commentary & Analysis


Financial Summary

Share Statistics NAGE Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $271.4 $337.9 31%
Shares Out (Mil) 84.6 27.3 59%
Institutional Ownership 67.2% 55.3% 42%
Float (Mil) 59.6 30.7 51%
Beta 2.06 0.56 93%
Avg Daily Volume (000s) 626 150 63%
Price Change
(52-week)
(64.3%) 56.7% 11%
Growth NAGE Industry
Median
Percentile
(All Stocks)
Sales (5yr) 16.9% 2.3% 77%
Net Income (5yr) 23.5% (4.8%) 78%
EPS (5yr) 21.2% 2.3% 70
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 59.5% (13.2%) 95%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 1 1 1
Current EPS ($0.010) $0.190 $0.290
Month Ago EPS ($0.010) $0.190 $0.290
# Rev Up 1 1 0
# Rev Down 1 0 1
Three Months Ago EPS $0.030 $0.240 $0.320
Year/Year Chg (114.3%) (5.0%) 120.0%
Financials NAGE Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $130 $421 29%
Net Income (TTM) (Mil) $19 $0 49%
EPS (TTM) $0.234 $0.100 48%
Operating Cash Flow (TTM) (Mil) $4 $12 36%
Net Cash Flow (TTM) (Mil) $11 $0 58%
Long-Term Debt (Q1) (Mil) $2 $44 19%
Enterprise Value (Q1) (Mil) $216 $334 27%
Valuation NAGE Industry
Median
Percentile
(All Stocks)
P/B 3.30 2.05 68%
P/E 16.2 16.4 40%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.8 0.7 36%
Ratios NAGE Industry
Median
Percentile
(All Stocks)
Gross Margin 64.3% 64.3% 76%
Net Margin 14.3% 1.6% 72%
ROA 19.0% 1.3% 96%
ROE 27.1% 5.3% 86%
Liabilities to Assets 28.0% 48.0% 20%
F-Score 5 4 51%

Niagen Bioscience, Inc. did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors